Cargando…

Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis

The available data, including experimental studies, clearly indicate an excessive intravascular activation of circulating platelets in multiple sclerosis (MS) and their hyper-responsiveness to a variety of physiological activators. Platelet activation is manifested as an increased adhesion and aggre...

Descripción completa

Detalles Bibliográficos
Autores principales: Saluk-Bijak, Joanna, Dziedzic, Angela, Bijak, Michal
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406904/
https://www.ncbi.nlm.nih.gov/pubmed/30717273
http://dx.doi.org/10.3390/cells8020110
_version_ 1783401431861035008
author Saluk-Bijak, Joanna
Dziedzic, Angela
Bijak, Michal
author_facet Saluk-Bijak, Joanna
Dziedzic, Angela
Bijak, Michal
author_sort Saluk-Bijak, Joanna
collection PubMed
description The available data, including experimental studies, clearly indicate an excessive intravascular activation of circulating platelets in multiple sclerosis (MS) and their hyper-responsiveness to a variety of physiological activators. Platelet activation is manifested as an increased adhesion and aggregation and is accompanied by the formation of pro-thrombotic microparticles. Activated blood platelets also show an expression of specific membrane receptors, synthesis many of biomediators, and generation of reactive oxygen species. Epidemiological studies confirm the high risk of stroke or myocardial infarction in MS that are ischemic incidents, strictly associated with incorrect platelet functions and their over pro-thrombotic activity. Chronic inflammation and high activity of pro-oxidative processes in the course of MS are the main factors identified as the cause of excessive platelet activation. The primary biological function of platelets is to support vascular integrity, but the importance of platelets in inflammatory diseases is also well documented. The pro-thrombotic activity of platelets and their inflammatory properties play a part in the pathophysiology of MS. The analysis of platelet function capability in MS could provide useful information for studying the pathogenesis of this disease. Due to the complexity of pathological processes in MS, medication must be multifaceted and blood platelets can probably be identified as new targets for therapy in the future.
format Online
Article
Text
id pubmed-6406904
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-64069042019-03-19 Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis Saluk-Bijak, Joanna Dziedzic, Angela Bijak, Michal Cells Review The available data, including experimental studies, clearly indicate an excessive intravascular activation of circulating platelets in multiple sclerosis (MS) and their hyper-responsiveness to a variety of physiological activators. Platelet activation is manifested as an increased adhesion and aggregation and is accompanied by the formation of pro-thrombotic microparticles. Activated blood platelets also show an expression of specific membrane receptors, synthesis many of biomediators, and generation of reactive oxygen species. Epidemiological studies confirm the high risk of stroke or myocardial infarction in MS that are ischemic incidents, strictly associated with incorrect platelet functions and their over pro-thrombotic activity. Chronic inflammation and high activity of pro-oxidative processes in the course of MS are the main factors identified as the cause of excessive platelet activation. The primary biological function of platelets is to support vascular integrity, but the importance of platelets in inflammatory diseases is also well documented. The pro-thrombotic activity of platelets and their inflammatory properties play a part in the pathophysiology of MS. The analysis of platelet function capability in MS could provide useful information for studying the pathogenesis of this disease. Due to the complexity of pathological processes in MS, medication must be multifaceted and blood platelets can probably be identified as new targets for therapy in the future. MDPI 2019-02-01 /pmc/articles/PMC6406904/ /pubmed/30717273 http://dx.doi.org/10.3390/cells8020110 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Saluk-Bijak, Joanna
Dziedzic, Angela
Bijak, Michal
Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis
title Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis
title_full Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis
title_fullStr Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis
title_full_unstemmed Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis
title_short Pro-Thrombotic Activity of Blood Platelets in Multiple Sclerosis
title_sort pro-thrombotic activity of blood platelets in multiple sclerosis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6406904/
https://www.ncbi.nlm.nih.gov/pubmed/30717273
http://dx.doi.org/10.3390/cells8020110
work_keys_str_mv AT salukbijakjoanna prothromboticactivityofbloodplateletsinmultiplesclerosis
AT dziedzicangela prothromboticactivityofbloodplateletsinmultiplesclerosis
AT bijakmichal prothromboticactivityofbloodplateletsinmultiplesclerosis